You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Non-V600 BRAF Mutations

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)

Not yet recruiting
  • NSCLC
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University
Sep 19, 2023

Solid Tumor Trial in Toronto (Binimetinib, Encorafenib)

Recruiting
  • Solid Tumor
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Sep 23, 2022

NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

Recruiting
  • Non-Small Cell Lung Cancer
  • +5 more
  • Toripalimab
  • +3 more
  • Guanzhou, Guangdong, China
    Guangdong Lung Cancer Institute, Guangdong Provincial People's H
Apr 4, 2023

Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI

Recruiting
  • Non-Small Cell Carcinoma of Lung, TNM Stage 4
  • +5 more
    • Aurora, Colorado
      University of Colorado, Cancer Center
    Nov 3, 2021

    Recurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma Trial in United States (trametinib, laboratory biomarker analysis,

    Completed
    Has Results
    • Recurrent Melanoma
    • +3 more
    • Washington, District of Columbia
    • +3 more
    May 4, 2021

    Aspirin in Combination With Trametinib and Dabrafenib

    Not yet recruiting
    • NSCLC
    • +4 more
    • Combind asprin with Trametinib and Dabrafenib
    • (no location specified)
    Aug 4, 2023

    BRAF V600-mutated Lung Carcinoma Treated With Combination of

    Completed
    • Non Small Cell Lung Cancer
    • BRAF V600 Mutation
      • Créteil, France
      • +1 more
      Jun 29, 2022

      Cancer Trial (Dabrafenib, Trametinib)

      Not yet recruiting
      • Cancer
      • (no location specified)
      May 25, 2023

      NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • +32 more
      • (no location specified)
      Mar 30, 2023

      Non Small Cell Lung Cancer Trial (HLX208+HLX10)

      Not yet recruiting
      • Non Small Cell Lung Cancer
      • HLX208+HLX10
      • (no location specified)
      Nov 30, 2022

      Advanced Solid Tumor, BRAF V600 Mutation Trial in United States (ABM-1310, Cobimetinib)

      Recruiting
      • Advanced Solid Tumor
      • BRAF V600 Mutation
      • San Francisco, California
      • +3 more
      Dec 30, 2022

      Dabrafenib Plus Trametinib In Rare BRAF V600E Mutation-Positive

      Not yet recruiting
      • Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
      • Non-investigational
      • (no location specified)
      May 11, 2023

      Associated Factors, and Clinical Outcomes of Prescribing

      Completed
      • BRAF v600 Mutated Metastatic Melanoma
        • East Hanover, New Jersey
          Novartis Pharmaceuticals
        Mar 28, 2023

        Cancer, BRAF V600 Mutation, Melanoma Trial (XP-102, Trametinib)

        Not yet recruiting
        • Cancer
        • +5 more
        • (no location specified)
        Aug 18, 2022

        BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer

        Recruiting
        • Metastatic Non-small Cell Lung Cancer
        • BRAF V600 Mutation
          • Lyon, Rhône Alpes, France
            CHU Lyon - Hôpital Cardio-Vasculaire et Pneumologique Louis Prad
          Sep 14, 2022

          Non-small-cell Lung Cancer Trial (HL-085+Vemurafenib)

          Not yet recruiting
          • Non-small-cell Lung Cancer
          • (no location specified)
          Jun 8, 2023

          Advanced Solid Tumor, BRAF V600 Mutation Trial in Nanchang, Jinan, Shanghai (ABM-1310)

          Not yet recruiting
          • Advanced Solid Tumor
          • BRAF V600 Mutation
          • Nanchang, Jiangxi, China
          • +2 more
          Aug 12, 2022

          Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the CNS

          Recruiting
          • Clinical Stage IV Cutaneous Melanoma AJCC v8
          • +3 more
          • Scottsdale, Arizona
          • +2 more
          Jan 4, 2023

          NSCLC Trial in Shanghai (HLX208)

          Recruiting
          • NSCLC
          • Shanghai, China
            Shanghai chest hospital
          Jan 5, 2022

          Colorectal Cancer, Colon Cancer, BRAF V600E Trial (Binimetinib)

          Not yet recruiting
          • Colorectal Cancer
          • +4 more
          • (no location specified)
          Aug 18, 2022

          Colorectal Cancer, BRAF V600E Mutation Positive Trial (Encorafenib Oral Capsule + Cetuximab)

          Not yet recruiting
          • Colorectal Cancer
          • BRAF V600E Mutation Positive
          • Encorafenib Oral Capsule + Cetuximab
          • (no location specified)
          Jan 30, 2023

          BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma Trial in Portland (Binimetinib,

          Recruiting
          • BRAF NP_004324.2:p.V600M
          • +6 more
          • Portland, Oregon
            Providence Portland Medical Center
          Aug 17, 2022

          Colorectal Cancer Metastatic Trial (Tunlametinib plus Vemurafenib, Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy

          Not yet recruiting
          • Colorectal Cancer Metastatic
          • Tunlametinib plus Vemurafenib
          • Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab
          • (no location specified)
          Aug 15, 2023

          BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma Trial in Guangzhou (Encorafenib)

          Completed
          • BRAF V600E Unresectable or Metastatic Melanoma
          • +2 more
          • Guangzhou, Guangdong, China
            Sun Yat-sen University Cancer Center
          Jun 9, 2022

          Primary Malignant Brain Tumor Trial in China (ABM-1310)

          Not yet recruiting
          • Primary Malignant Brain Tumor
          • Beijing, Beijing, China
          • +3 more
          May 28, 2023